Tag: evidence appraisal
-
Lp(a)HORIZON: A Missed Primary Endpoint, a Press Release, and the Numbers That Are Still Missing
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. This post covers a corporate topline announcement about a completed cardiovascular outcomes trial in a listed company’s pivotal asset. Every result-layer number below is attributed as a company statement; trial design, population, and…
-
Aficamten Met Both Primary Endpoints in Nonobstructive HCM. Its Effect Size Nearly Overlaps With the Trial That Didn’t
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, and not medical advice. Both trials discussed below are peer-reviewed, randomized, double-blind, placebo-controlled phase 3 trials published in the New England Journal of Medicine. The comparison drawn between them is an indirect, cross-trial…
